Electromyography Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The electromyography devices market size is expected to increase from USD 1.26 billion in 2025 to USD 1.34 billion in 2026 and reach USD 1.96 billion by 2031, growing at a CAGR of 7.81% over 2026-2031. This report is Segmented by Product Type (Stationary, Portable, Wearable, Integrated EMG-EEG), Study Type (Surface, Needle, High-Density, Nerve Conduction), Application (Neurology, Intra-Operative Monitoring, Orthopedics & Sports, Pain Management, Research), End User (Hospitals, Clinics, Ascs, and More), and Geography (North America, and More). Market Forecasts are in Value (USD).

Global Electromyography Devices Market Trends and Insights

Rising Prevalence of Neuromuscular Disorders

Global cases of ALS, muscular dystrophy, and myasthenia gravis are climbing, supported by the U.S. CDC’s 12% rise in ALS prevalence between 2020 and 2024. EMG remains the definitive test for distinguishing motor-neuron from peripheral pathologies, and clinicians now order repeat studies every 6-12 months to track disease progression. Universal-coverage markets permit easier reimbursement for follow-up testing, doubling device utilization per patient. WHO’s 2024 update lists neurological conditions at 9.4% of global DALYs, underscoring the diagnostic gap that the electromyography devices market can fill.

Rapid Growth of the Aging Population

Japan’s over-65 cohort hit 29.1% in 2023 and is driving an 18% forecast rise in neurodegenerative disease by 2030. China plans 15,000 new neurology beds by 2028, each budgeted for at least one stationary EMG console. Concentrated demand pockets in Northeast Asia and Southern Europe reward vendors that localize manuals and expand service footprints. South Korea’s regulator approved 14 new device models in 2024, illustrating momentum among domestic producers.

High Capital and Maintenance Costs

Advanced consoles can cost up to USD 150,000, exceeding many regional-hospital budgets. Brazil directed only 18% of its USD 42 million neurology spend to EMG in 2024, channeling the rest to MRI and CT. Certified pre-owned programs from Natus and Nihon Kohden - priced 40% below new - are one workaround, already validated by Argentina’s 2025 approvals for six refurbished models.

Other drivers and restraints analyzed in the detailed report include:

• Technology Shift to Portable & Wireless Systems
• Integration of AI-Driven Analytics
• Shortage of Trained Professionals

Segment Analysis

Stationary consoles retained 57.11% of the electromyography devices market share in 2025, buoyed by multi-modal capability and high throughput in hospital neuro-labs. They continue to anchor the electromyography devices market size for comprehensive diagnostics, yet their growth is modest as capital budgets tighten. Wearable patches, priced below USD 200 each, are clocking an 11.43% CAGR and are reshaping the electromyography devices market by enabling continuous monitoring in sports and home settings. Portable eight- to sixteen-channel units occupy a strategic middle ground, especially in outpatient and ambulatory theatres where space is scarce. Integrated EMG-EEG rigs serve sleep-medicine and epilepsy researchers, commanding premium prices but remaining a niche.

Accelerating adoption of portability plays to ambulatory centers that lack floor space for large carts. Compumedics noted 22% growth in portable sales during 2024, validating a shift toward laptop-sized amplifiers. Next-generation stationary systems now feature swappable modules, letting buyers scale channel counts without entire replacements, while wearables benefit from algorithmic denoising that lifted concordance with clinical consoles to 88% in 2024 trials. Sustainability pressures in Europe further favor modular upgrades over wholesale turnover.

Surface methods held 46.52% share in 2025 because they are painless and quick, especially for gait and rehab assessment. High-density arrays, however, are growing 10.25% annually as universities and start-ups chase granular motor-unit data. Such systems contribute disproportionately to the electromyography devices market size through higher unit prices and service contracts. Needle EMG remains irreplaceable for radiculopathy and myopathy diagnosis, and is bundled with nerve-conduction studies that insurers reimburse separately.

Commercial availability of 64- to 256-channel grids, priced USD 5,000-15,000, cuts procurement hurdles for research labs. Surface EMG’s role is stable as wearables absorb some share yet still use surface electrodes. Diabetes screening programs in India and China are expanding nerve-conduction volumes, further lifting procedural demand. FDA Class II classification keeps regulatory barriers low, accelerating market entry for both high-density and surface devices.

Complete Report Scope:

• By Product Type
  • Stationary EMG Systems
  • Portable EMG Systems
  • Wearable EMG Patches
  • Integrated EMG-EEG Systems
• By Study Type
  • Surface EMG
  • Needle EMG
  • High-density EMG
  • Nerve Conduction Studies
• By Application
  • Neurology Diagnostics
  • Intra-operative Monitoring
  • Orthopedics & Sports Medicine
  • Pain Management & Rehabilitation
  • Others
• By End User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Sports Rehab Centers
  • Home Care Settings
  • Academic & Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.41% share in 2025 on the back of Medicare reimbursement for nerve-conduction studies, a mature electrodiagnostic lab network, and 23 FDA device clearances in 2024. Canada widened coverage for home-based EMG, targeting remote ALS patients, while Mexico’s private chains upgraded neuro labs despite public-sector fiscal pressure. Competitive rivalry is concentrated, with Medtronic, Natus, and Cadwell controlling most hospital tenders, and Delsys and Noraxon carving sports and research niches.

Asia-Pacific is forecast to register the fastest CAGR at 9.12%, propelled by China’s USD 8.8 billion infrastructure drive and Japan’s subsidies for 200 municipal hospitals. India earmarked USD 120 million for neurology equipment, 40% of which targets EMG. South Korea exported USD 4.2 billion in medical devices, including EMG systems, underscoring rising regional manufacturing capability. Australia’s sports-science ecosystem drives incremental demand, while Southeast Asian markets prioritize cost-efficient portables for rural outreach.

Europe occupies a solid mid-tier position. Germany approved 18 new EMG products in 2024, and France widened reimbursement for EMG-guided botulinum injections. The U.K. launched a pilot to deploy wearable EMG in physiotherapy centers. In the Middle East and Africa, GCC states allocated USD 1.8 billion to health infrastructure, spotlighting neuro-centers of excellence. South Africa’s private hospitals adopt portable EMG for spine surgery, whereas public uptake is budget-limited. South America remains modest; Brazil bought 340 systems in 2024, yet Argentina favors refurbished units amid fiscal constraints.

List of Companies Covered in this Report:

• AD Instruments
• Allengers Medical Systems Ltd.
• Ambu
• Biometrics
• Cadwell
• Clarity Medical Pvt. Ltd.
• Cometa
• Compumedics
• Delsys Inc.
• Electrical Geodesics Inc.
• iWorx Systems Inc.
• Medtronic
• Micromed S.p.A.
• Natus Medical
• NCC Medical
• Neurosoft
• Nihon Kohden
• Noraxon USA Inc.
• OT Bioelettronica
• Thought Technology
• Zynex Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support